Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Miler, Marijana; Gabaj, Nora Nikolac; Ćelap, Ivana; Grazio, Simeon; Tomašić, Vedran; Bišćanin, Alen; Mitrović, Joško; Đerek, Lovorka; Morović‐Vergles, Jadranka; Vrkić, Nada; Štefanović, Mario

doi:10.1007/s00296-021-05016-w

Cited by 7 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between the TNFα SNP rs1800629 (-308G > A) and response to anti-TNFα agents in in ammatory disorders has been the subject of several investigations with con icting results (26, [39][40][41][42]. In rheumatoid arthritis, spondyloarthropathy and IBD meta-analyses the TNFα -308A allele carriers was found to respond less to anti-TNFα drugs (40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

et al. 2023

View full text Add to dashboard Cite

Anti-tumor necrosis factor alpha (anti-TNFα) inhibitors are used extensively for the management of moderate to severe in ammatory bowel disease (IBD) in both adult and pediatric patients. Unfortunately, not all patients show optimal response to induction therapy, while others lose their response over time, for reasons yet poorly understood. We report on a pharmacokinetic/pharmacogenetic approach to monitor the therapy with anti-TNFα in a real-world cohort of seventy-nine pediatric patients affected by IBD that was analyzed retrospectively. We evaluated serum concentrations of in iximab, adalimumab and related anti-drug antibodies (ADAs), and single nucleotide polymorphisms (SNPs) in genes involved in immune processes and in ammation on anti-TNFα response. We found a signi cant association between the SNP in TNFα promoter (-308G > A) and clinical remission without steroids in patients on in iximab therapy. Additionally, a potential connection between HLA-DQA1*05 genetic variant carriers and a higher risk of anti-TNFα immunogenicity emerged.

show abstract

Section: Discussionmentioning

confidence: 99%

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The proinflammatory cytokine TNF- inhibits collagen synthesis and enhances collagen degradation by increasing the production of MMR9. Various studies suggest the influence of genetic polymorphisms of the TNFA gene (responsible for TNF- expression) in various chronic diseases [28,29,30]. In another study, it was suggested that IL6 (the gene responsible for IL6 expression) is a biomarker of health status in the elderly [31].…”

Section: Stress Inflammation and Skinmentioning

confidence: 99%

Pathophysiological and Genetic Aspects of the Brain–Skin Axis: The Role of Stress and Inflammation in Skin Aging

Borzykh

2022

jour

View full text Add to dashboard Cite

Aging is a genetically programmed process that is influenced by a large number of external and internal factors. The most frequently discussed factor accelerating aging is UV radiation. But among other factors that accelerate aging, we should not forget about chronic stress and chronic inflammation. These factors are interrelated with each other and can mutually enhance the effect of each other. In particular, chronic stress and inflammation can also affect skin aging. So, the skin is an organ of stress factors, as well as sources of some stress factors. Since the topic of the effects of chronic stress and inflammation, and especially its genetic aspects, are quite rare in the literature, the purpose of this review was to combine the available data on the pathogenesis and genetic aspects of stress and inflammation when exposed to skin aging.

show abstract

Vitamin D, microbiota, and inflammatory bowel disease

Cantorna,

Arora

2024

Feldman and Pike's Vitamin D

View full text Add to dashboard Cite

Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy

Cited by 7 publications

References 34 publications

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study

Pathophysiological and Genetic Aspects of the Brain–Skin Axis: The Role of Stress and Inflammation in Skin Aging

Vitamin D, microbiota, and inflammatory bowel disease

Contact Info

Product

Resources

About